文献速递生殖医学妇科

生育治疗与癌症:系统综述与荟萃分析

Fertility treatment and cancers-the eternal conundrum: a systematic review and meta-analysis.
PubMed 文献 · Hum Reprod · 2021-01-01

总体FT未显著增加乳腺癌、卵巢癌或子宫内膜癌风险,宫颈癌发生率反而显著降低;但IVF和克罗米芬治疗亚组卵巢癌发生率显著升高,交界性卵巢肿瘤风险亦显著增加。

要点

  • 总体生育治疗不显著增加乳腺癌、卵巢癌或子宫内膜癌风险,宫颈癌风险显著降低。
  • IVF亚组卵巢癌风险显著升高(OR 1.32),克罗米芬亚组亦升高(OR 1.40)。
  • 交界性卵巢肿瘤风险显著增加(OR 1.69),需关注特定治疗与肿瘤亚型的关联。

核心结论

  • 总体生育治疗不显著增加乳腺癌、卵巢癌或子宫内膜癌发生率,且可能降低宫颈癌发生率。
  • IVF和克罗米芬治疗与卵巢癌发生率升高显著相关,交界性卵巢肿瘤风险亦显著增加。

研究设计与样本

  • 系统综述与荟萃分析,检索Cochrane Library、EMBASE、Medline和Google Scholar至2019年12月。

主要发现

  • 宫颈癌发生率在FT组显著低于无FT组:OR 0.68(95% CI 0.46-0.99)。
  • 乳腺癌(OR 0.86;95% CI 0.73-1.01)和子宫内膜癌(OR 1.28;95% CI 0.92-1.79)发生率在FT组与无FT组间无显著差异。
  • 总体卵巢癌发生率无显著差异(OR 1.19;95% CI 0.98-1.46),但交界性卵巢肿瘤风险显著增加(OR 1.69;95% CI 1.27-2.25)。
  • IVF亚组卵巢癌发生率显著升高(OR 1.32;95% CI 1.03-1.69),克罗米芬亚组亦显著升高(OR 1.40;95% CI 1.10-1.77)。
  • IVF亚组乳腺癌(OR 0.75;95% CI 0.61-0.92)和宫颈癌(OR 0.58;95% CI 0.38-0.89)发生率显著低于无FT组。

关键数值与推荐

  • 主要结局为FT组与无FT组的乳腺癌、卵巢癌、子宫内膜癌和宫颈癌发生率。
  • 采用随机效应模型计算合并OR值,并进行meta回归和八项亚组分析。

临床怎么用

  • 总体生育治疗对乳腺癌、卵巢癌和子宫内膜癌风险令人安心,宫颈癌风险可能降低。
  • 接受IVF或克罗米芬治疗的患者应关注卵巢癌风险,尤其是交界性卵巢肿瘤,需个体化咨询与监测。

局限性

  • 数据集大且研究时间跨度广,存在显著临床异质性,结果需谨慎解读。
  • 排除非英文文献、未发表研究和摘要可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does fertility treatment (FT) significantly increase the incidence of breast, ovarian, endometrial or cervical cancer? SUMMARY ANSWER: Overall, FT does not significantly increase the incidence of breast, ovarian or endometrial cancer and may even reduce the incidence of cervical cancer. WHAT IS KNOWN ALREADY: Infertility affects more than 14% of couples. Infertility and nulliparity are established risk factors for endometrial, ovarian and breast cancer, yet the association with FT is more contentious. STUDY DESIGN, SIZE, DURATION: A literature search was carried out using Cochrane Library, EMBASE, Medline and Google Scholar up to December 2019. Peer-reviewed studies stating cancer incidence (breast, ovarian, endometrial or cervical) in FT and no-FT groups were identified. Out of 128 studies identified, 29 retrospective studies fulfilled the criteria and were included (n = 21 070 337). PARTICIPANTS/MATERIALS, SETTING, METHODS: In the final meta-analysis, 29 studies were included: breast (n = 19), ovarian (n = 19), endometrial (n = 15) and cervical (n = 13), 17 studies involved multiple cancer types and so were included in each individual cancer meta-analysis. Primary outcome of interest was cancer incidence (breast, ovarian, endometrial and cervical) in FT and no-FT groups. Secondary outcome was cancer incidence according to specific fertility drug exposure. Odds ratio (OR) and random effects model were used to demonstrate treatment effect and calculate pooled treatment effect, respectively. A meta-regression and eight sub-group analyses were performed to assess the impact of the following variables, maternal age, infertility, study size, outliers and specific FT sub-types, on cancer incidence. MAIN RESULTS AND THE ROLE OF CHANCE: Cervical cancer incidence was significantly lower in the FT group compared with the no-FT group: OR 0.68 (95% CI 0.46-0.99). The incidences of breast (OR 0.86; 95% CI 0.73-1.01) and endometrial (OR 1.28; 95% CI 0.92-1.79) cancers were not found to be significantly different between the FT and no-FT groups. Whilst overall ovarian cancer incidence was not significantly different between the FT and no-FT groups (OR 1.19; 95% CI 0.98-1.46), separate analysis of borderline ovarian tumours (BOT) revealed a significant association (OR 1.69; 95% CI 1.27-2.25). In further sub-group analyses, ovarian cancer incidence was shown to be significantly higher in the IVF (OR 1.32; 95% CI 1.03-1.69) and clomiphene citrate (CC) treatment group (OR 1.40; 95% CI 1.10-1.77), respectively when compared with the no-FT group. Conversely, the incidences of breast (OR 0.75; 95% CI 0.61-0.92) and cervical cancer (OR 0.58; 95% CI 0.38-0.89) were significantly lower in the IVF treatment sub-group compared to the no-FT group. LIMITATIONS, REASONS FOR CAUTION: The large, varied dataset spanning a wide study period introduced significant clinical heterogeneity. Thus, results have to be interpreted with an element of caution. Exclusion of non-English citations, unpublished work and abstracts, in order to ensure data accuracy and reliability was maintained, may have introduced a degree of selection bias. WIDER IMPLICATIONS OF THE FINDINGS: The results for breast, ovarian, endometrial and cervical cancer are reassuring, in line with previously published meta-analyses for individual cancers but the association between IVF and CC treatment and an increase in ovarian cancer incidence requires additional work to understand the potential mechanism driving this association. In particular, focusing on (i) discriminating specific treatments effects from an inherent risk of malignancy; (ii) differential risk profiles among specific patient sub-groups (refractory treatment and obesity); and (iii) understanding the impact of FT outcomes on cancer incidence. STUDY FUNDING/COMPETING INTEREST(S): This study did not receive any funding. The authors have no financial, personal, intellectual and professional conflicts of interest to declare. PROSPERO REGISTRATION NUMBER: CRD42019153404.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Barcroft JF, Galazis N, Jones BP, et al. Fertility treatment and cancers-the eternal conundrum: a systematic review and meta-analysis. Hum Reprod. 2021. PMID: 33586777. doi:10.1093/humrep/deaa293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。